NASDAQ: OLMAOlema Pharmaceuticals Inc Stock
$9.51+0.07 (+0.74%)
Updated Jun 18, 2026
OLMA Price
$9.51
Fair Value Price
$0.54
Market Cap
$830.67M
52 Week Low
$4.02
52 Week High
$36.26
P/E
-4.68x
P/B
1.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$185.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$149M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OLMA Overview
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OLMA's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OLMA
Ranked#447 of 465
Ranked#447 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important OLMA news, forecast changes, insider trades & much more!
OLMA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OLMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OLMA ($9.51) is overvalued by 1,656.45% relative to our estimate of its Fair Value price of $0.54 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OLMA ($9.51) is not significantly undervalued (1,656.45%) relative to our estimate of its Fair Value price of $0.54 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OLMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OLMA due diligence checks available for Premium users.
Valuation
OLMA fair value
Fair Value of OLMA stock based on Discounted Cash Flow (DCF)
Price
$9.51
Fair Value
$0.54
Overvalued by
1,656.45%
OLMA ($9.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OLMA ($9.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OLMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OLMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.68x
Industry
15.77x
Market
9.47x
OLMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.73x
Industry
4.95x
OLMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OLMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$53.1M
Profit Margin
0%
OLMA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$530.6M
Liabilities
$50.2M
Debt to equity
0.1
OLMA's short-term assets ($513.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OLMA's short-term assets ($513.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OLMA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OLMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$46.0M
Investing
$4.5M
Financing
$45.7M
OLMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OLMA vs Biotech Stocks
Olema Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.